pubmed.ncbi.nlm.nih.gov

Ion channelopathies in functional GI disorders - PubMed

  • ️Fri Jan 01 2016

Review

Ion channelopathies in functional GI disorders

Arthur Beyder et al. Am J Physiol Gastrointest Liver Physiol. 2016.

Abstract

In the gastrointestinal (GI) tract, abnormalities in secretion, absorption, motility, and sensation have been implicated in functional gastrointestinal disorders (FGIDs). Ion channels play important roles in all these GI functions. Disruptions of ion channels' ability to conduct ions can lead to diseases called ion channelopathies. Channelopathies can result from changes in ion channel biophysical function or expression due to mutations, posttranslational modification, and accessory protein malfunction. Channelopathies are strongly established in the fields of cardiology and neurology, but ion channelopathies are only beginning to be recognized in gastroenterology. In this review, we describe the state of the emerging field of GI ion channelopathies. Several recent discoveries show that channelopathies result in alterations in GI motility, secretion, and sensation. In the epithelium, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) or CFTR-associating proteins result in channelopathies with constipation or diarrhea as phenotypes. In the muscle, mutations in the SCN5A-encoded voltage-gated sodium channel NaV1.5 are associated with irritable bowel syndrome. In the sensory nerves, channelopathies of voltage-gated sodium channels NaV1.7 and NaV1.9 (encoded by SCN9A, SCN11A, respectively) manifest by either GI hyper- or hyposensation. Recent advances in structural biology and ion channel biophysics, coupled with personalized medicine, have fueled rapid discoveries of novel channelopathies and direct drug targeting of specific channelopathies. In summary, the emerging field of GI ion channelopathies has significant implications for functional GI disease stratification, diagnosis, and treatment.

Keywords: channelopathy; gastrointestinal; ion channel; mutation.

Copyright © 2016 the American Physiological Society.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.

NBCI publications on “channelopathies” since the first publication in 1991 (Accessed on June 8th, 2016). Solid black line is an exponential fit of the data.

Fig. 2.
Fig. 2.

IBS-associated SCN5A mutations. Black, no functional abnormalities (6/20, 30%); blue, loss-of-function (13/20, 65%); red, gain-of-function (1/20, 5%).

Similar articles

Cited by

References

    1. Abriel H. Cardiac sodium channel Na(v)1.5 and interacting proteins: physiology and pathophysiology. J Mol Cell Cardiol 48: 2–11, 2010. - PubMed
    1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991–2003, 2010. - PMC - PubMed
    1. Ashcroft FM. From molecule to malady. Nature 440: 440–447, 2006. - PubMed
    1. Bagal SK, Brown AD, Cox PJ, Omoto K, Owen RM, Pryde DC, Sidders B, Skerratt SE, Stevens EB, Storer RI, Swain NA. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem 56: 593–624, 2013. - PubMed
    1. Beyder A, Farrugia G. Targeting ion channels for the treatment of gastrointestinal motility disorders. Therap Adv Gastroenterol 5: 5–21, 2012. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources